Halozyme Therapeutics, Inc. (0J2O.L)
LSE - LSE Delayed price. Currency in USD
Add to watchlist
At close: 06:28PM BST
| Previous close | 43.37 |
| Open | 44.06 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 43.17 - 44.23 |
| 52-week range | 30.09 - 44.71 |
| Volume | |
| Avg. volume | 1,670 |
| Market cap | 70.151M |
| Beta (5Y monthly) | 1.26 |
| PE ratio (TTM) | 0.14 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Halozyme to Participate in Upcoming Investor Conferences
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Nicole LaBrosse, Chief Financial Officer, is scheduled to present and host investor meetings at the following investor conferences:
- PR Newswire
HALOZYME REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATING RESULTS
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results for the first quarter ended March 31, 2024, and provided an update on its recent corporate activities and outlook.
- PR Newswire
Mahesh Krishnan Elected to Halozyme's Board of Directors
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the election of Mahesh Krishnan, M.D. to its Board of Directors. Dr. Krishnan has more than 20 years of experience in healthcare, biotechnology and health services.
© 2024 Yahoo. All rights reserved.